Trials
4 active
9 in total · 4 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “BHV-7000 50 mg. Participants will take blinded investigational product (IP) once daily”In the company’s words, NCT06309966 on ClinicalTrials.gov
- Tested for
- Focal Epilepsy (3 trials), Familial Erythromelalgia
- Main trialPhase 2/3
- “The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.”In the company’s words, NCT06309966 on ClinicalTrials.gov
- Other names
- opakalim
Other drugs for Focal Epilepsy
- CenobamateSK Life Science, Inc. · Phase 3
- VormatroginePraxis Precision Medicines · Phase 3
- RAP-219Rapport Therapeutics Inc. · Phase 3
- AzetukalnerXenon Pharmaceuticals Inc. · Phase 3
- NRTX-1001Neurona Therapeutics · Phase 1/2
- SPN-817Supernus Pharmaceuticals, Inc. · Phase 2
Coming up3
- DecPhase 2/3 trial completes · ClinicalTrials.gov
- DecPhase 2 trial completes · ClinicalTrials.gov
- Nov 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Active, not recruiting | Oct 2026 | Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | |
| Phase 2/3Active, not recruiting | Dec 2026 | A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | |
| Phase 2Enrolling by invitation | Dec 2026 | Long-term Safety and Tolerability of BHV-7000 | |
| Phase 1Active, not recruiting | Nov 2027 | A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia | |
| Phase 2/3Completed | 15 Jan 2025 | BHV-7000 Acute Treatment of Bipolar Mania | |
| Phase 2/3Terminated | 12 Mar 2026 | A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures | |
| Phase 2Terminated | 25 Apr 2025 | BHV-7000 Open-Label Extension Bipolar Mania Study | |
| Phase 2Completed | 7 Nov 2025 | Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression | |
| Phase 2Completed | 18 Mar 2026 | Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026